本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688217 证券简称：睿昂基因 公告编号：2023-064 上海睿昂基因科技股份有限公司 关于召开 2023 年第四次临时股东大会的通知 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年第四次临时股东大会 召开日期时间：2023 年 8 月 24 日 14 点 30 分 召开地点：上海市奉贤区汇丰西路 1817 弄 147 号睿昂基因会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 8 月 24 日 至 2023 年 8 月 24 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 本次股东大会审议议案及投票股东类型 | 序号 | 议案名称 | 投票股东类型 | | --- | --- | --- | | | | 股股东 A | | 累积投票议案 | | | | 1.00 | 《关于补选公司第二届董事会独立董事的议 | 应选 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2023-065 上海睿昂基因科技股份有限公司 关于公司独立董事辞职及补选独立董事的公告 公司独立董事候选人姜广策先生已取得独立董事资格证书，尚未参加上海 证券交易所科创板独立董事网络课程培训，作为第二届董事会独立董事候选人 其已承诺将参加上海证券交易所最近一期科创板独立董事培训，并取得科创板 独立董事培训记录证明。 三、独立董事的独立意见 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、关于独立董事辞职的情况说明 上海睿昂基因科技股份有限公司（以下简称"公司"）董事会于近日收到独 立董事徐伟建先生提交的辞职报告，独立董事徐伟建先生因个人原因，申请辞 去公司第二届董事会董事及第二届董事会审计委员会委员、薪酬与考核委员会 委员、提名委员会委员的职务，辞职后，徐伟建先生不再担任公司任何职务。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海睿昂基 因科技股份有限公司章程》（以下简称"《公司章程》"）等相关规定，徐伟建 先生的辞职将导致公司独立董事人数少于董事 ...

2023 年第一季度报告 证券代码：688217 证券简称：睿昂基因 上海睿昂基因科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | 变动幅度(%) | | | 营业收入 | | 56,884,419.55 | | 17.84 | | 归属于上市公司股东的净利 | | 1,290,913.02 | | 不适用 | | 润 | | | | | | 归属于上市公司股东 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 25%[17]. - The company's operating revenue for 2022 was CNY 424,298,139.43, representing a year-on-year increase of 45.83% compared to CNY 290,951,595.17 in 2021[24]. - The net profit attributable to shareholders for 2022 was CNY 40,473,558.80, a decrease of 14.49% from CNY 47,332,599.14 in 2021[24]. - The basic earnings per share for 2022 was CNY 0.73, down 23.16% from CNY 0.95 in 2021[25]. - The company achieved a revenue of 424.30 million yuan in 2022, representing a year-on-year growth of 45.83%[35]. - The net profit attributable to the parent company was 40.47 million yuan, a decrease of 14.49% compared to the previous year[35]. - The company reported a significant increase in testing business revenue, contributing to the overall rise in operating income[25]. - The company experienced a net loss of CNY 2,331,194.58 in the first quarter of 2022, followed by a profit of CNY 23,613,993.54 in the second quarter[26]. Research and Development - The company has not achieved profitability since its listing, indicating ongoing investment in research and development[7]. - The company emphasizes significant funding needs for R&D projects, fixed asset investments, and marketing network upgrades[6]. - Research and development expenses accounted for 15.18% of operating revenue in 2022, a decrease of 8.41 percentage points from 23.59% in 2021[25]. - The company invested 64.43 million yuan in R&D in 2022, accounting for 15.18% of the total revenue[37]. - The company has developed 3 core front-end technologies, 6 advanced molecular diagnostic application technologies, and 2 forward-looking reserve technologies in the field of molecular diagnostics[91]. - The company has obtained 55 patent authorizations, including 46 invention patents, 8 utility model patents, and 1 design patent, with 30 new patent applications filed during the year[95]. - The company has developed a multi-factor artificial intelligence algorithm for accurate prognosis assessment models for specific cancer patients[92]. - The company has launched a rapid FISH technology that reduces the traditional hybridization process time from 16-24 hours to just 1-2 hours[93]. Market Strategy and Expansion - The company is focused on expanding its market presence and developing new products and technologies[6]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[17]. - The company is actively collaborating with AstraZeneca and Merck in the field of precision diagnostics, enhancing its market presence and technological capabilities[69]. - The company aims to enhance its market presence through the promotion of its lymphoma gene rearrangement product, which has been recommended in national diagnostic guidelines[65]. - The company has established partnerships with three major hospitals to enhance its testing capabilities and expand its service offerings[17]. - The company has developed a direct sales marketing network covering over 300 top-tier hospitals nationwide[32]. - The company plans to increase market share in the follow-up and existing patient markets by enhancing initial patient conversion rates through a physician-patient software platform[191]. Risks and Challenges - The company has disclosed potential risks in its management discussion and analysis section, urging investors to be cautious[4]. - The company is facing risks related to new product development, registration, and technology iteration, which could impact its competitive advantage[112][115][116]. - The company is exposed to market competition risks due to the influx of new entrants and larger firms in the in vitro diagnostics market[119]. - The company is facing risks related to the renewal of medical device licenses, which could impact normal operations if not managed properly[121]. Operational Highlights - The company has established an automated laboratory capable of handling up to 20,000 tests per day, with AI cloud platform integration allowing for rapid report generation within 10 minutes[49]. - The company has accumulated a database of over 200,000 blood cancer detection data annually, enhancing its capabilities in clinical relevance analysis and data modeling[49]. - The company has a workforce of 503 employees, with over 57% holding a bachelor's degree or higher[32]. - The company has a total of 80 R&D personnel, accounting for 15.90% of the total workforce, with an average salary of CNY 18.96 million[104]. Product Development and Innovation - The company has developed a high-quality sales team and established a market strategy center to enhance its marketing system and support sales operations[46]. - The company is committed to the national strategy of "precision medicine," focusing on providing accurate genetic testing for cancer patients[50]. - The company has developed 36 antigen detection reagents in the immunodiagnostic field, achieving first-class registration for these products[94]. - The company has developed a unique database for primer-probe design technology, enhancing the specificity and efficiency of molecular diagnostics[92]. - The company is in the clinical trial phase for multiple new products, including the BCR-ABL fusion gene quantitative detection kit and JAK2 mutation detection kit[159]. Financial Position and Cash Flow - The net cash flow from operating activities for 2022 was CNY 73,068,987.33, a decrease of 6.28% from CNY 77,966,980.44 in 2021[24]. - Cash and cash equivalents increased by 65.25% to ¥203,850,876.14, up from ¥123,356,044.84 in the previous year[149]. - Trade receivables rose by 56.26% to ¥255,816,952.93, compared to ¥163,711,813.43 in the previous year, reflecting increased revenue scale[149]. - The company’s long-term assets under construction increased by 97.38% to ¥115,681,731.45, up from ¥58,609,551.51 in the previous year due to payments for new factory projects[149]. Regulatory and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[8]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[10]. - The company has not violated decision-making procedures for external guarantees[11]. - The company has successfully registered multiple medical devices, enhancing its product portfolio and market presence[161].

证券代码：688217 证券简称：睿昂基因 公告编号：2023-037 重要内容提示： 会议问题征集：投资者可于 2023 年 4 月 18 日（星期二）12:00 前访问网 址 https://eseb.cn/13wwi8rQsoM 进行会前提问，上海睿昂基因科技股份有限公司 （以下简称"公司"）将通过本次业绩暨现金分红说明会，在信息披露允许范围 内就投资者普遍关注的问题进行回答。 一、说明会类型 公司已于 2023 年 4 月 10 日在上海证券交易所网站（www.sse.com.cn）披露 了《上海睿昂基因科技股份有限公司 2022 年年度报告》及《上海睿昂基因科技 股份有限公司 2022 年年度报告摘要》。为便于广大投资者更加全面深入地了解 公司 2022 年年度经营业绩、发展战略和现金分红等情况，公司定于 2023 年 4 月 18 日（星期二）15:00-16:00 在"价值在线"（www.ir-online.cn）召开上海睿昂基因 科技股份有限公司 2022 年度业绩暨现金分红说明会，与投资者进行沟通和交流， 广泛听取投资者的意见和建议。 二、说明会召开的时间、地点和方式 会议召开时间：2023 ...

Financial Performance - The company's operating revenue for 2021 was ¥290,951,595.17, representing a 2.11% increase compared to ¥284,925,965.97 in 2020[22]. - The net profit attributable to shareholders for 2021 was ¥47,332,599.14, which is a 22.26% increase from ¥38,713,469.94 in 2020[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥34,522,634.60, showing a slight increase of 0.79% from ¥34,252,757.14 in 2020[22]. - The net cash flow from operating activities for 2021 was ¥77,966,980.44, an increase of 11.20% compared to ¥70,111,641.75 in 2020[22]. - The net assets attributable to shareholders at the end of 2021 were ¥888,814,968.69, reflecting a 37.44% increase from ¥646,685,380.98 at the end of 2020[22]. - The total assets at the end of 2021 were ¥947,531,998.67, which is a 33.13% increase from ¥711,712,727.06 at the end of 2020[22]. - The company achieved a total revenue of RMB 290.95 million in 2021, representing a year-on-year growth of 2.11%[31]. - The sales of self-produced reagents reached RMB 223.47 million, an increase of 18.07% compared to the previous year[31]. - The net profit attributable to the parent company was RMB 47.33 million, up 22.26% year-on-year[31]. - The revenue from blood disease molecular diagnostic kits was RMB 174.49 million, reflecting a year-on-year increase of 23.46%[32]. Research and Development - The company reported a significant increase in R&D investment to support its rapid development phase, with no cash dividends or stock bonuses proposed for 2021[5]. - The R&D investment accounted for 23.59% of operating income, a decrease of 2.51 percentage points from the previous year[23]. - Research and development expenses for 2021 amounted to CNY 68.64 million, representing 23.59% of the company's revenue for the period[37]. - The total R&D investment for the year was CNY 68.64 million, a decrease of 7.69% from the previous year, with R&D investment accounting for 23.59% of operating revenue, down from 26.10%[90]. - The company emphasizes the importance of R&D team building and has a strong core R&D team with members from renowned universities and research institutions[100]. - The company is committed to rapid clinical translation of research results, ensuring that promising scientific findings are efficiently developed into clinical products[99]. Product Development and Market Strategy - The company is actively pursuing new product development and technological advancements in the field of in vitro diagnostics (IVD)[11]. - The company signed an exclusive distribution agreement with Otsuka Pharmaceutical for the WT1 mRNA testing kit, enhancing its product line in the molecular diagnostics market for blood diseases[34]. - The company is focusing on precision diagnostics for blood diseases, solid tumors, and infectious diseases, expanding its product offerings in immune diagnostics[46]. - The company plans to launch 15 new fusion gene products in the first quarter of 2022, further solidifying its leading position in the domestic leukemia molecular testing market[55]. - The company is focusing on expanding its product offerings in the molecular diagnostic field, with several new products in the pipeline[94]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market share, with a focus on biotech firms[188]. Risk Management - The company has a comprehensive risk management section in its report, highlighting potential risks associated with its future plans and strategies[6]. - The company emphasizes the importance of investor awareness regarding the risks associated with forward-looking statements in its report[6]. - The company faces risks related to new product development, including potential failures due to technical challenges and high costs[106]. - The company is facing risks related to the ongoing COVID-19 pandemic, which may affect hospital operations and product sales[117]. Corporate Governance - The company has maintained a stable board composition, with no significant changes in shareholding among directors and supervisors during the reporting period[187]. - The total remuneration for the chairman and general manager, Xiong Hui, is 10,176,397 CNY, with no changes in shareholding during the reporting period[187]. - The company has a total of 10 directors and supervisors, with varying ages and tenures, ensuring a diverse leadership team[187]. - The company held a total of 23 board meetings in 2021, with all resolutions passed without any objections[199]. - The company has not faced any penalties from securities regulatory authorities in the past three years[198]. Financial Integrity - The company has not reported any non-operating fund occupation by controlling shareholders or related parties, ensuring financial integrity[7]. - The company has received a standard unqualified audit report from its accounting firm, affirming the accuracy of its financial statements[5]. - The company has established various technology platforms, including fluorescence PCR and next-generation sequencing, to support its diagnostic services[102]. Market Expansion - The company is expanding its market presence in Asia, targeting a 30% increase in market share within the next two years[189]. - The company is exploring acquisition opportunities in the healthcare sector to diversify its portfolio[191]. - The company plans to improve its market share in the follow-up and existing patient segments by utilizing patient-doctor software platforms to increase patient retention[173]. Future Outlook - Future outlook suggests continued expansion with a projected revenue increase of 20% for the upcoming fiscal year, driven by new product launches and market penetration strategies[188]. - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming to reach $1.875 billion[189]. - The company is investing heavily in R&D, with a budget allocation of 42.12 million aimed at developing innovative technologies and products[188].

证券代码：688217 证券简称：睿昂基因 上海睿昂基因科技股份有限公司投资者关系活动记录表 编号：2022-004 | --- | --- | --- | |-------------------------|-----------------------------------------------------------------------------------------------------------------------------------|--------------------| | 投资者活动类 别 | 特定对象调研 分析师会议 业绩说明会 新闻发布会 现场参观 □其他 | 媒体采访 路演活动 | | 公司接待 成员名单 | 公司董事长、总经理 熊慧； 公司董事、副总经理 熊钧； 财务总监、董事会秘书 李彦； 思泰得总经理 何俊彦； 市场部总监 乔明敏 | | | | 经济日报 李治国 | | | | 光大证券 林小伟 | | | | 中信证券 刘媛媛 | | | 参与单位名称 及人员姓名 | 浙江大健康 吴征涛 | | | | 高特佳资本 叶永泉 谢益彬 厚扬资本 苏卉 ...

证券代码：688217 证券简称：睿昂基因 上海睿昂基因科技股份有限公司投资者关系活动记录表 编号：2022-005 | --- | --- | |-------------------------|--------------------| | 投资者活动类 别 | 媒体采访 路演活动 | | 公司接待 成员名单 | | | | | | | | | | | | | | | 参与单位名称 及人员姓名 | | | | | | | | | | | | | | | 时间 | | | 地点 | | | 形式 | | | --- | --- | |------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

2022 年第三季度报告 证券代码：688217 证券简称：睿昂基因 上海睿昂基因科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 上年同期增 | 年初至报告期 | 末比上年同期 | | | | 减变动幅度 | 末 | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 99,695,696.51 | 36.69 | 272,407,21 ...

2022 年半年度报告 公司代码：688217 公司简称：睿昂基因 上海睿昂基因科技股份有限公司 2022 年半年度报告 1 / 191 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、 准确性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法 律责任。 二、 重大风险提示 公司已在本报告中描述可能存在的风险，敬请查阅"第三节管理层讨论与分析"之"五、风 险因素"部分，请投资者注意投资风险。 三、 公司全体董事出席董事会会议。 √适用 □不适用 本报告涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质性承诺， 敬请投资者注意投资风险。 四、 本半年度报告未经审计。 五、 公司负责人熊慧、主管会计工作负责人李彦及会计机构负责人（会计主管人员）李彦 声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 九、 是否存在被控股股东及其关联方非经营性占用资金情况 否 否 ...